(K-125174) Támogató: Nemzeti Kutatás, Fejlesztés és Innovációs Iroda
(PD-132851) Támogató: OTKA
(K-135683) Támogató: OTKA
(K-139230) Támogató: NKFIH
(NVKP_16-1-2016-0042) Támogató: OTKA
Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009)
Támogató: EFOP-VEKOP
(2020-1.1.6-JÖVŐ-2021-00010)
(2020-1.1.6-JOVO-2021-00013)
(TKP2021-EGA-25)
(ÚNKP-23-4-I-SE-17)
We have previously reported that, in aortic rings, 18:1 lysophosphatidic acid (LPA)
can induce both vasodilation and vasoconstriction depending on the integrity of the
endothelium. The predominant molecular species generated in blood serum are poly-unsaturated
LPA species, yet the vascular effects of these species are largely unexplored. We
aimed to compare the vasoactive effects of seven naturally occurring LPA species in
order to elucidate their potential pathophysiological role in vasculopathies. Vascular
tone was measured using myography, and thromboxane A2 (TXA2) release was detected
by ELISA in C57Bl/6 mouse aortas. The Ca2+-responses to LPA-stimulated primary isolated
endothelial cells were measured by Fluo-4 AM imaging. Our results indicate that saturated
molecular species of LPA elicit no significant effect on the vascular tone of the
aorta. In contrast, all 18 unsaturated carbon-containing (C18) LPAs (18:1, 18:2, 18:3)
were effective, with 18:1 LPA being the most potent. However, following inhibition
of cyclooxygenase (COX), these LPAs induced similar vasorelaxation, primarily indicating
that the vasoconstrictor potency differed among these species. Indeed, C18 LPA evoked
a similar Ca2+-signal in endothelial cells, whereas in endothelium-denuded aortas,
the constrictor activity increased with the level of unsaturation, correlating with
TXA2 release in intact aortas. COX inhibition abolished TXA2 release, and the C18
LPA induced vasoconstriction. In conclusion, polyunsaturated LPA have markedly increased
TXA2-releasing and vasoconstrictor capacity, implying potential pathophysiological
consequences in vasculopathies.